Neos Therapeutics Inc. initiated an underwritten public offering of its common shares.
Neos plans to grant underwriters the option to purchase up to an additional 15% of the number of common shares sold in the offering.
Cowen and Co. and BMO Capital Markets are acting as joint book-running managers for the offering.